Abstract | BACKGROUND: Treatment of latent tuberculosis infection with isoniazid for 9 months is complicated by poor patient adherence and the need for close follow-up of side effects, especially hepatotoxicity. Shorter and safer regimens are needed. OBJECTIVE: DESIGN: Multicenter, randomized, open-label trial. SETTING:
Tuberculosis clinics located in university hospitals in Canada, Brazil, and Saudi Arabia. PATIENTS: INTERVENTION: MEASUREMENTS: Grade 3 to 4 drug-related adverse events resulting in drug discontinuation (primary outcome), and on-time treatment completion, grade 1 to 2 drug-related adverse events, and changes in liver enzymes and hematologic variables (secondary outcomes). RESULTS: Seventeen of 422 participants who started isoniazid therapy developed grade 3 to 4 adverse events compared with 7 of 418 who started rifampin therapy (risk difference [ rifampin minus isoniazid], -2.3% [95% CI, -5% to -0.1%]; P = 0.040). Grade 3 or 4 hepatitis occurred in 16 of 422 isoniazid recipients compared with 3 of 418 rifampin recipients (risk difference, -3.1% [CI, -5% to -1%]; P = 0.003). Grade 1 or 2 adverse events attributed to study drugs occurred with similar frequency. Asymptomatic reduction in platelet and leukocyte counts were more frequent in rifampin recipients. More patients completed rifampin treatment (78%) than isoniazid treatment (60%) (difference, 18% [CI, 12% to 24%]; P < 0.001]). LIMITATION: The study did not measure efficacy, and the open-label design may increase the chance of bias in ascertainment of adverse events. CONCLUSION:
|
Authors | Dick Menzies, Richard Long, Anete Trajman, Marie-Josée Dion, Jae Yang, Hamdan Al Jahdali, Ziad Memish, Kamran Khan, Michael Gardam, Vernon Hoeppner, Andrea Benedetti, Kevin Schwartzman |
Journal | Annals of internal medicine
(Ann Intern Med)
Vol. 149
Issue 10
Pg. 689-97
(Nov 18 2008)
ISSN: 1539-3704 [Electronic] United States |
PMID | 19017587
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antitubercular Agents
- Transaminases
- Isoniazid
- Rifampin
|
Topics |
- Adolescent
- Adult
- Antitubercular Agents
(adverse effects)
- Chemical and Drug Induced Liver Injury
(enzymology, etiology)
- Drug Administration Schedule
- Female
- Humans
- Isoniazid
(adverse effects)
- Liver
(enzymology)
- Male
- Patient Compliance
- Patient Dropouts
- Prospective Studies
- Rifampin
(adverse effects)
- Transaminases
(metabolism)
- Tuberculosis
(drug therapy)
- Young Adult
|